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Variability in viral load measurements using nucleic acid ampliﬁcation techniques (NAT) has a signiﬁcant
impact on the management of EpsteineBarr virus (EBV)-associated diseases, and has highlighted a need
for standardisation of these measurements. The aim of this collaborative study was to evaluate the
suitability of a range of candidate reference materials to harmonise EBV viral load measurements in a
wide range of NAT assays. Candidate materials included lyophilised and liquid whole virus preparations
of the EBV B95-8 strain, and preparations of Namalwa and Raji cells. Variability between the individual
laboratory mean estimates for each candidate was 2.5 log10 copies/mL. The agreement between labo-
ratories was improved when the potency of each candidate was expressed relative to the lyophilised
B95-8 preparation. The results of the study indicate the suitability of this candidate as the 1st WHO
International Standard for EBV for NAT. It was established in October 2011 by the WHO's Expert Com-
mittee on Biological Standardisation with an assigned potency of 5  106 International Units (IU) (NIBSC
code 09/260). It is intended to be used for the calibration of secondary reference materials, used in EBV
NAT assays, in IU, thereby improving the comparability of patient viral load measurements.
© 2016 The Authors. Published by Elsevier Ltd on behalf of International Alliance for Biological
Standardization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
EpsteineBarr virus (EBV) is a ubiquitous herpesvirus with a high
worldwide seroprevalence. Primary infection is generally asymp-
tomatic but can lead to infectious mononucleosis in adolescents
and young adults. Following primary infection the virus establishes
lifelong persistence in B cells. EBV is associated with a number of
malignancies, including; Burkitt's lymphoma, Hodgkin and non-
Hodgkin lymphoma, gastric and nasopharyngeal carcinoma
(NPC), in immunocompetent individuals. In immunocompromised
individuals (transplant recipients, AIDS patients, and those with
congenital immunodeﬁciencies), EBV is associated with lympho-
proliferative diseases. Post-transplant lymphoproliferative disorder
(PTLD) is a major complication among haematopoietic stem cell
and solid organ transplant recipients, with primary EBV infection
being a major risk factor [1,2].er).
the Acknowledgements.
Ltd on behalf of International Allian
c-nd/4.0/).Viral load measurements using nucleic acid ampliﬁcation
techniques (NAT) are important for the diagnosis and management
of EBV-associated infections [1e4]. The monitoring of EBV DNA in
blood compartments is widely applied in high-risk PTLD and NPC
patients and is critical for early intervention in order to prevent the
development of disease and formonitoring the response to therapy.
However, there is no clear consensus on the timing or frequency of
testing, or the best blood component to monitor. In the case of NPC,
virus is principally measured in plasma, since EBV DNA is derived
from the tumour cells, and exists mainly as naked DNA. Meanwhile,
in PTLD, EBV is both cell-associated and is released into the cell-free
fraction of blood. Although peripheral blood mononuclear cells,
plasma and whole blood have all been used successfully to detect
EBV in transplant recipients, some studies suggest that whole blood
is the most appropriate sample to monitor as it captures both cell-
free and cell-associated components (reviewed in Refs. [1e4]).
A wide range of NAT assays are used in the diagnosis and
management of EBV-associated diseases. These are predominantly
laboratory-developed tests (LDTs), although a number of com-
mercial kits and analyte-speciﬁc reagents (ASR) are available. Thesece for Biological Standardization. This is an open access article under the CC BY-NC-
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depending on the specimen type. Primers and probes used in the
ampliﬁcation step target different regions of the EBV genome, with
some targets being present in multiple copies. In addition, the
quantiﬁcation controls used to determine the concentration of viral
DNA present may comprise either a plasmid clone of the PCR target,
quantiﬁed viral DNA or virus particles, or cells containing speciﬁc
copy numbers of the EBV genome. These controls mayormay not be
included in the extraction step. Consequently, results may be re-
ported as EBV copies/mL, copies/mg, or copies/number of cells,
depending on which control is used. Given the heterogeneity of
these NAT-based assay systems, and the lack of traceability to a
standardised reference system, it is difﬁcult to compare viral load
measurements between different laboratories and to evaluate
therapeutic strategies. Indeed, variability in the performance of EBV
NAT has been documented [5,6]. These studies have highlighted the
need for an internationally-accepted reference standard for EBV.
EBV viral load thresholds for therapeutic intervention vary by local
experience, reinforcing the need for a universal calibrator. In the
absence of such a standard, individual laboratories and treatment
centres apply their ownmanagement algorithms which are speciﬁc
to their individual viral load assay.
The World Health Organisation's (WHO) Expert Committee on
Biological Standardisation (ECBS) establishes reference standards
for biological substances used in the prevention, treatment or
diagnosis of human disease. WHO International Standards are
recognised as the highest order of reference for biological sub-
stances. As they are developed through the processes of biological
standardisation, they are arbitrarily assigned a potency in Inter-
national Units (IU). Their primary purpose is to calibrate secondary
references used in routine laboratory assays, in terms of the IU,
thereby providing a uniform result reporting system, and trace-
ability of measurements, independent of the method used [7].
Proposals for the development of the 1st WHO International
Standard for EBV were presented at the ﬁrst Standardisation of
Genome Ampliﬁcation Techniques (SoGAT) Clinical Diagnostics
meeting held at NIBSC in June 2008 [8], and options for source
materials and formulation of the candidate standard were dis-
cussed [9]. This study describes the preparation and evaluation of
candidate materials and the establishment of the optimal candidate
as the 1st WHO International Standard for EBV for NAT.
2. Materials and methods
2.1. Preparation of candidate stock materials
Candidate materials comprised liquid and lyophilised cell-free
live virus preparations of the prototype laboratory EBV strain
B95-8 [10], and preparations of Namalwa [11] and Raji [12] cells,
both of which contain integrated copies of an EBV viral genome.
These strains represent well characterised EBV genomes, which are
frequently used in the preparation of control materials for EBV NAT
assays. They are all classiﬁed as Type 1 viruses, based on the
sequence of EBNA-2 and EBNA-3 genes, and were sourced from the
European Collection of Authenticated Cell Cultures (ECACC), Salis-
bury, UK. Namalwa and Raji cells contain 2 and 50e60 copies of the
EBV genome respectively, which are present as episomes.
A cell culture supernatant sample of EBV B95-8 strain was
prepared by propagation of B95-8 cells incubated with 30 mg/mL
12-O-tetradecanoylphorbol-13-acetate (TPA) (adapted from
Ref. [13]). The culture ﬂuid was clariﬁed by low speed centrifuga-
tion and the virus pelleted by ultracentrifugation. An EBV B95-8
stock was prepared by reconstituting the virus pellets and pool-
ing in a total volume of 200 mL 10 mM TriseHCl buffer (pH 7.4),
containing 0.5% human serum albumin (HSA) (TriseHSA buffer).The HSA used in the preparation of the B95-8 candidates was
derived from licensed products. The plasma pools fromwhich these
products were derived were screened and tested negative for anti-
HIV-1, HBsAg, and HCV RNA. The Namalwa and Raji cells were
propagated in RPMI-1640 medium containing 10% FCS, supple-
mented with 2 mM L-glutamine, 100 IU/mL penicillin and 100 mg/
mL streptomycin, and harvested at the log phase of growth.
2.2. EBV DNA quantiﬁcation
The concentration of EBV DNA in the B95-8 candidates was
determined at NIBSC, using a quantitative real-time PCR LDT.
Brieﬂy, 400 mL of sample (1/1000 dilution of stock) was extracted
using the QIAamp® MinElute® Virus Spin Kit (QIAGEN, Hilden,
Germany), on the QIAcube® instrument. A ﬁve microlitre sample of
puriﬁed nucleic acid was then ampliﬁed by real-time PCR [14] using
the LightCycler® 480 Instrument (Roche Applied Science, Man-
nheim, Germany). The target was quantiﬁed against serial dilutions
of a plasmid clone of the PCR target. The EBV DNA concentration
was also assessed at NIBSC using three commercial EBV assays
(Roche LightCycler® EBV Quant Kit, Nanogen EBV QPCR Alert Kit
and Argene EBV R-gene™ Quantiﬁcation Kit), and in four clinical
laboratories in the UK using a range of LDT and commercial assays.
The geometric mean virus concentration from all assays, in ‘copies/
mL’, was used to determine a consensus EBV concentration for the
stock.
2.3. Preparation of candidate bulks
The B95-8 bulk preparations were formulated to contain
approximately 1  107 EBV ‘copies/mL’ in a ﬁnal volume of 6.4 L
TriseHSA buffer, containing 0.1% trehalose, and mixed for a total of
30 min using a magnetic stirrer. Approximately 250 mL of the liquid
bulk was dispensed in 1 mL aliquots into 2 mL Sarstedt screw cap
tubes and stored at 70 C. The remaining bulk volume was imme-
diately processed for lyophilisation of the product, NIBSC code 09/
260. The Namalwa and Raji candidates were formulated to contain
1  106 cells/mL in PBS. Cells were aliquotted in 1 mL volumes into
2 mL Sarstedt screw cap tubes and stored at 70 C. Samples of each
candidate (liquid B95-8 n ¼ 24, lyophilised B95-8 n ¼ 24, Namalwa
n¼ 18 and Raji cells n ¼ 18) were quantiﬁed using the EBV real-time
PCR LDT (as described in Section 2.2), in order to determine the ho-
mogeneity of each candidate prior to dispatch for collaborative study.
2.4. Filling and lyophilisation of the B95-8 candidate
The ﬁlling and lyophilisation of the B95-8 candidate was per-
formed at NIBSC. The ﬁlling was performed in a negative pressure
isolator (Metall and Plastic GmbH, Radolfzell, Germany), containing
the entire ﬁlling line and is interfaced with a CS150 freeze dryer
(Serail, Arguenteil, France). The bulk material was kept at 4 C
throughout the ﬁlling process, and stirred constantly using a
magnetic stirrer. The bulk was dispensed into 5 mL screw cap glass
vials in 1 mL volumes, using a FVF5060 ﬁlling machine (Bausch &
Strobel, Ilshofen, Germany). The homogeneity of the ﬁll was
maintained by on-line check-weighing of the wet weight, and vials
outside the deﬁned speciﬁcation were discarded.
Filled vials were partially stoppered with halobutyl 14 mm
diameter cruciform closures and lyophilised in a CS150 freeze
dryer. Vials were loaded onto the shelves at 50 C and held at this
temperature for 4 h. A vacuum was applied to 270 mb over 1 h,
followed by ramping to 30 mb over 1 h. The temperature was then
raised to 40 C, and the vacuum maintained at this temperature
for 42.5 h. The shelves were ramped to 25 C over 15 h before
releasing the vacuum and back-ﬁlling the vials with nitrogen. The
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isolator, and the isolator decontaminated with formaldehyde
before removal of the product. The sealed vials are stored at 20 C
at NIBSC under continuous temperature monitoring for the lifetime
of the product.
Assessments of residual moisture and oxygen content, as an
indicator of vial integrity after sealing, were determined for twelve
vials of the lyophilised product. The residual moisture was deter-
mined by non-invasive near-infrared (NIR) spectroscopy (MCT
600P, Process Sensors, Corby, UK). NIR results were then correlated
to Karl Fischer (using calibration samples of the same excipient,
measured using both NIR and Karl Fischer methods) to give % w/w
moisture readings. The oxygen content was measured using a
Lighthouse Infra-Red Analyzer (FMS-750, Lighthouse Instruments,
Charlottesville, USA).
2.5. Stability assessment of the lyophilised B95-8 candidate
The stability of the lyophilised candidate 09/260 is being
assessed in an on-going accelerated thermal degradation study at
NIBSC in order to predict the stability of the product when stored at
the recommended temperature of 20 C. Vials of the freeze-dried
product are being held at70 C,20 C, 4 C, 20 C, 37 C, 45 C. At
speciﬁed time points during the life of the product, three vials are
removed from storage at each temperature and EBV DNA quantiﬁed
using the real-time PCR LDT described in Section 2.2.
2.6. Study participants
Twenty-eight participants representing 16 countries partici-
pated in the collaborative study, and are listed in the Acknowl-
edgements. Participants were selected for their experience in EBV
NAT and geographic distribution. They represented mainly clinical
laboratories, but also included manufacturers of in vitro diagnostic
devices (IVDs), reference and research laboratories. All partici-
pating laboratories are referred to by a code number, allocated at
random, and not representing the order of listing in the Acknowl-
edgements. Where a laboratory returned data using different assay
methods, the results were analysed separately, as if from different
laboratories, and are referred to as, for example, laboratory 1A, 1B
etc.
2.7. Study design
Study samples were coded as samples 1e4 and were as follows;
sample 1, lyophilised B95-8 (09/162); sample 2, liquid frozen B95-
8; sample 3, liquid frozen Namalwa cells; sample 4, liquid frozen
Raji cells. Samples were shipped to participating laboratories by
courier on dry ice, with speciﬁc instructions for storage and
reconstitution.
Participants were requested to test dilutions of each sample
using their routine NAT assay for EBV on four separate occasions,
using a fresh vial of each sample in each independent assay. The
lyophilised sample 1was to be reconstitutedwith 1mL of nuclease-
free water and left for a minimum of 20 min with occasional
agitation before use. Meanwhile, study samples 2e4 were to be
thawed and vortexed brieﬂy before use. For quantitative assays,
participants were requested to test a minimum of two serial ten-
fold dilutions within the linear range of the assay. For qualitative
assays, participants were requested to test ten-fold serial dilutions
of each sample in the ﬁrst assay, in order to determine the assay
end-point, and then to ﬁne-tune the end-point by testing a mini-
mum of two half-log10 serial dilutions either side of the pre-
determined end-point, for subsequent assays. Participants were
requested to dilute samples 1e4 using the sample matrix speciﬁc totheir individual assay, and to extract each dilution prior to ampli-
ﬁcation. Participants were requested to report the viral load in
‘copies/mL’ (positive/negative for qualitative assays) for each dilu-
tion of each sample and return results, including details of meth-
odology used, to NIBSC for analysis.
2.8. Statistical methods
Qualitative and quantitative assay results were evaluated
separately. In the case of qualitative assays, for each laboratory and
assay method, data from all assays were pooled to give a number of
positive out of number tested at each dilution step. A single ‘end-
point’ for each dilution series was calculated, to give an estimate of
‘NAT detectable units/mL’, as described previously [15]. It should be
noted that these estimates are not necessarily directly equivalent to
a genuine genome equivalent/mL. In the case of quantitative assays,
analysis was based on the results supplied by the participants.
Results were reported as ‘copies/mL’ although the relationship to
genuine genome equivalence numbers is unknown, with individual
laboratories using different methods and quantiﬁcation controls to
determine their copy number. For each assay run, a single estimate
of log10 ‘copies/mL’ was obtained for each sample, by taking the
mean of the log10 estimates of ‘copies/mL’ across replicates, after
correcting for any dilution factor. A single estimate for the labora-
tory and assay method was then calculated as the mean of the log10
estimates of ‘copies/mL’ across assay runs.
Overall analysis was based on the log10 estimates of ‘copies/mL’
or ‘NAT detectable units/mL’. Overall mean estimates were calcu-
lated as the means of all individual laboratories. Variation between
laboratories (inter-laboratory), was expressed as standard de-
viations (SD) of the log10 estimates and percentage geometric co-
efﬁcient of variation (%GCV) [16] of the actual estimates. The ability
of a candidate standard to reduce the inter-laboratory variability in
EBV viral load measurements was assessed by calculating the po-
tency of one candidate relative to the other study samples. The
relative potency of, for example, sample 3 relative to sample 1 was
calculated for each individual assay as the difference in estimated
log10 ‘units per mL’ (test sample e candidate standard) plus an
assigned value in IU/mL for the candidate standard.
Variation within laboratories and between assays (intra-labo-
ratory), was expressed as the SDs of the log10 estimates and %GCVs
of the individual assay mean estimates. The signiﬁcance of the
inter-laboratory variation relative to the intra-laboratory variation
was assessed by an analysis of variance. A component of variance
analysis was used to assess the relative magnitude of the inter-
laboratory and intra-laboratory variability.
3. Results
3.1. Validation of study samples and stability of the lyophilised
candidate
Evaluation of multiple aliquots of each study sample for EBV
DNA concentration by NAT, prior to dispatch, indicated that the
homogeneity of EBV content was similar for all study samples (2SD
less than 0.2 log10 ‘copies/mL’ for each sample). The mean ﬁll
weight and CV of the ﬁll for 09/260 were determined from mea-
surements from every 100th vial (n ¼ 60) and were 1 g and 0.23%,
respectively. The mean residual moisture, as determined by Karl
Fischer and NIR, was 0.7% and 0.48%, respectively (CV ¼ 9.5%),
based on measurements from 11 vials. The mean residual oxygen
content was 0.18% (CV ¼ 26.6%), based on measurements from 12
vials. The CVs of the ﬁll mass and mean residual moisture were
within acceptable limits for a WHO International Standard [7]. The
residual oxygen content waswithin the NIBSCworking limit of 1.1%.
Table 1
Thermal stability of lyophilised EBV (B95-8), 09/260, at different storage temperatures.
Temperature (C) Mean log10 ‘copies/mL’a (difference in log10 ‘copies/mL’ from 20 C baseline sample)
4 months 8 months 12 months 26 months 41 months 47 months 60 months 72 months
70 6.87 6.99 7.04 7.01 7.02 7.02 6.98 6.80
20 6.88 6.97 7.05 7.00 7.07 6.94 7.06 6.88
4 6.91 (0.03) 7.00 (0.03) 7.09 (0.04) 7.02 (0.02) 7.10 (0.03) 6.91 (0.03) 7.06 (0.00) 6.84 (0.04)
20 6.96 (0.08) 7.02 (0.05) 7.09 (0.04) 7.03 (0.03) 7.11 (0.04) 7.05 (0.11) 7.04 (0.02) 6.85 (0.03)
37 6.96 (0.08) 6.94 (0.03) 7.13 (0.08) 7.04 (0.04) 7.15 (0.08) 7.11 (0.17) 6.99 (0.07) 6.86 (0.02)
45 6.99 (0.11) 7.06 (0.09) 7.15 (0.10) 7.11 (0.11) 7.11 (0.04) 7.09 (0.15) 7.10 (0.04) 6.80 (0.08)
a Mean results from single extractions from 3 vials at each time-point and temperature, each ampliﬁed in triplicate.
J.F. Fryer et al. / Biologicals 44 (2016) 423e433426The stability of the lyophilised B95-8 virus, 09/260, is being
assessed at NIBSC in accelerated thermal degradation studies. Vials
of 09/260 are stored at elevated temperatures, and at speciﬁc time
points vials are removed for testing using the EBV real-time PCR
LDT. The mean estimated log10 ‘copies/mL’ for three vials stored at
each temperature for 4, 8 12,26, 41, 47, 60 and 72months are shown
in Table 1. The differences (log10 ‘copies/mL’) from the 20 C
baseline sample are also shown. A negative value indicates a drop in
potency relative to the 20 C baseline. The 95% conﬁdence in-
tervals for the differences are approximately ±0.05 log10 based on a
pooled estimate of the SD between individual vial test results. The
majority of temperatures and time points do not show any drop in
potency compared with the 20 C baseline samples. There is no
observable change in potency across the course of 72months at any
temperature, within the limits of the assay variability.
3.2. Data received
Data were received from all 28 participating laboratories. Par-
ticipants performed a variety of different assaymethods, with some
laboratories performingmore than one assaymethod. The variables
in assay methodologies used are detailed in Table 2. In total, data-
sets were received from 36 quantitative assays, and 2 qualitative
assays. The majority of participants prepared dilutions of study
samples 1e4 using either plasma or whole blood, however, other
diluents (PBS, DMEM, 10 mM Tris, and nuclease-free water) were
also used. The extent of the dilutions performed varied slightly
between each laboratory. Extractions were predominantly auto-
mated. All datasets reported the use of real-time PCR technology.
Fourteen participants used commercial assays and reagents (20
datasets), while 12 participants used LDTs (14 datasets). Two par-
ticipants used both commercial and LDTs (4 datasets). Given the
range of assay variables, and the fact that no two assays were
identical, it was not possible to group assays and perform analysis
according to the methodology used.
Laboratory 4 (A&B) had results, after correction for dilution
factors, that were high at higher dilutions (104& 105) comparedTable 2
Summary of assay methodologies.
Assay component Variable
Diluent Plasma, whole blood, urine, PBS, nuclease-free water.
Extraction (automated) QIAGEN QIAsymphony SP and RG Q, BioRobot, QIAcube, an
MagNA Pure Compact.
Extraction (manual) Roche High Pure Viral Nucleic Acid Kit; Nanogen EXTRAge
Kits, and QIAamp DSP Virus Kit; Cepheid afﬁgene® DNA Ex
2 h then þ95 C for 10 min) in ‘Cracking buffer’.
Ampliﬁcation kit/ASR
(commercial assays)
Nanogen EBV Q-PCR Alert; Argene EBV R-gene™; QIAGEN
afﬁgene® EBV trender and SmartEBV™; ELITech/Epoch EB
EBV gene target EBNA-1, EBNA-2, BNRF1 p143, BXLF1, EBER1, BALF5 and B
Ampliﬁcation platform Roche LightCycler® 1.5, 2.0 and 480 systems; Applied Bios
Agilent Mx3000P® QPCR System; QIAGEN Rotor-Gene™ Qto other dilutions. Also the results for undiluted samples were high
compared with those from the 101 to 103 dilutions. Only the
results from the 101, 102 and 103 dilutions were used for sub-
sequent analysis. Laboratory 6 had no data for sample 4 from assay
4. They reported some estimates of sample 3 as 0 at the 103
dilution. All data for sample 3 at 103 were excluded. Laboratory 7
reported one estimate for sample 3 from assay 2 at the 102 dilu-
tion as outside the range of the assay. All estimates for sample 3 at
this dilution for this assay were excluded. Laboratory 9 continued
their dilution range until they obtained ‘undetectable’ for their
quantitative assays. Only estimates greater than 100 copies/mL
were used in subsequent calculations. Laboratory 14 had results
that were ‘undetected’ or below the linear range of the assay at
higher dilutions. Only results from the ﬁrst two dilution steps were
used in subsequent analysis. Laboratory 16 had very low estimates
at higher dilutions. Only estimates greater than 50 copies/mL were
used in subsequent calculations. Laboratory 18 had results for
sample 3 at higher dilutions that were low relative to the neat
sample. They were also the lowest estimates for all samples. Only
the estimates from the neat sample for sample 3 were used, in case
the higher dilutions were giving estimates outside the range of the
assay. Laboratory 20 had some results at 103.5 and 104 that
appeared inconsistent with other dilutions. Only the results from
the 101,102 and 103 dilutions were used for subsequent analysis.
Laboratory 21 had ‘positive but non-quantiﬁable’ results for some
replicates at the 103 dilution. All data at the 103 dilution were
excluded. Apart from the cases noted above, all other data were
included in the analyses.
3.3. Potency estimates and inter-laboratory variation
The laboratory mean estimates for each study sample for
quantitative assays (in log10 ‘copies/mL’) and qualitative assays (in
log10 ‘NAT detectable units/mL’) are shown in Supplementary
Tables 1 and 2 respectively. The individual laboratory mean esti-
mates for each assay are also shown in histogram form in Fig. 1.
Individual laboratory results in Fig. 1 are colour coded according tod EZ1 Advanced; bioMerieux NucliSENS® easyMag®; Roche MagNA Pure LC and
n®, EXTRAcell®, and EXTRAblood®; QIAGEN QIAamp (DNA Blood and DNA) Mini
traction Kit; bioMerieux NucliSENS® miniMAG®; and heat treatment (þ60 C for
artus® EBV (LC and RG) PCR Kits; Roche LightCycler® EBV Quant Kit; Cepheid
V ASR; and Quantiﬁcation of HHV4 PrimerDesign™ Ltd.
amHI-W.
ystems™ 7300, 7500, 7500 Fast, and 7900 HT Fast Real-Time PCR Systems;
and Rotor-Gene™ 3000; and Cepheid SmartCycler™ II.
Fig. 1. Individual laboratory mean estimates for study samples 1 (A), 2 (B), 3 (C), and 4 (D), obtained using qualitative or quantitative NAT assays. Each box represents the mean
estimate from each laboratory assay and is labelled with the laboratory code number. The results from the qualitative assays are labelled Q. The results are colour coded according to
the diluent used in the assay (dark grey, whole blood; light grey, plasma; white, other).
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plasma; white, other) and show no apparent relationship between
matrix and potency estimate. The results for samples 1e4 show
considerable variation in the viral load reported between different
assays, with estimates differing by up to 2.5 log10 copies/mL
(Supplementary Table 1). The estimates of ‘NAT detectable units/
mL’ from the qualitative assay from laboratory 17 are low for all
samples. However, the estimates from the qualitative assay from
laboratory 20 are closer to the estimates from the majority of
quantitative assays. It should be noted that the results from quali-
tative and quantitative assays are not directly comparable, as ‘NAT
detectable units/mL’ determined by end-point dilution and esti-
mates of ‘copies/mL’ from quantitative assays are not necessarily
equivalent. The estimates of ‘copies/mL’ from laboratory 10 are
lower than other laboratories for all samples. The results fromTable 3
Overall mean estimates and inter-laboratory variation (log10 ‘copies/mL’ for quantitativ
excluding laboratories 10, 12, 16 and 17. nd, Not determined.
Sample Assay No. of datasets
1 Qualitative 2
Quantitative 36
Excluding 10, 12, 16 & 17 32
2 Qualitative 2
Quantitative 36
Excluding 10, 12, 16 & 17 32
3 Qualitative 2
Quantitative 36
Excluding 10, 12, 16 & 17 32
4 Qualitative 2
Quantitative 36
Excluding 10, 12, 16 & 17 32laboratory 16 are also generally low for samples 1, 2 and 4. The
quantitative results from laboratory 17 are low for samples 3 and 4
(cell-based material) but not for samples 1 and 2 (cell-free virus). It
is also notable that laboratory 12 has estimates that are central or
slightly lower compared with the majority of other laboratories for
samples 1 and 2, but estimates that are high compared to other
laboratories for the cellular materials samples 3 and 4.
Table 3 shows the overall mean estimates for each study sample
for quantitative and qualitative assays, along with the SD (of log10
estimates) and the %GCV (of actual estimates). SD and %GCV values
were not calculated for the qualitative assays, as there were only
two laboratories performing qualitative assays. For samples 1e4,
the SD for quantitative assays is ~0.6 log10 copies/mL, and the %GCV
is 270e330%. These values are consistent with the 2.5 log10 copies/
mL range of potency estimates. Comparison of the overall meane or ‘NAT-detectable units/mL’ for qualitative assays), and for quantitative assays
Mean Range SD %GCV
6.04 5.49e6.59 nd nd
6.71 5.03e7.56 0.58 277
6.80 5.61e7.56 0.48 205
5.97 6.20e5.41 nd nd
6.75 5.02e7.54 0.57 270
6.85 5.74e6.70 0.46 188
4.64 3.83e5.46 nd nd
5.92 4.41e6.82 0.60 294
5.99 4.87e6.82 0.48 205
6.20 5.96e6.45 nd nd
7.45 5.96e8.56 0.63 327
7.56 6.67e8.56 0.49 209
Fig. 2. Potencies of sample 2 relative to sample 1 (A), sample 3 relative to sample 1 (B),
and sample 4 relative to sample 1(C), for each quantitative and qualitative assay. Units
are expressed as candidate log10 IU/mL in both cases. Each box represents the relative
potency for each laboratory assay and is labelled with the laboratory code number. The
results from the qualitative assays are labelled Q. The results are colour coded ac-
cording to the diluent used in the assay (dark grey, whole blood; light grey, plasma;
white, other).
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bulk sample 2 indicates that there was a small drop in potency of
0.04 log10 upon freeze-drying, which was statistically signiﬁcant
(p ¼ 0.029). Table 3 also shows the overall mean and inter-
laboratory variation for all quantitative assays excluding the re-
sults from laboratories 10, 12, 16 and 17. These laboratories were
noted above as having either low estimates, or an apparent differ-
ential efﬁciency for cellular material compared with the cell-free
virus preparations (samples 3 and 4 compared to samples 1 and
2), and did not share similarities in assay methodology. After
excluding these laboratories, the SDs for samples 1e4 are reduced
to 0.5 log10, and the %GCVs are reduced to 200%. This level of inter-
laboratory variability is similar to that observed in the collaborative
study to establish the 1st WHO International Standard for HCMV
for NAT [17]. This comparison demonstrates that the large overall
variability observed between results does not arise from data from
a few individual laboratories which are markedly at variance with
those from the majority of laboratories. Thus there is no justiﬁca-
tion for excluding these laboratories simply because of the results
obtained, and the comparisons are presented for illustration only.
3.4. Relative potency determination
The expression of the potency of each study sample relative to a
candidate (as described in the statistical methods section) allows
an assessment of the suitability of each candidate for the stand-
ardisation of EBV NAT assays. The relative potencies (candidate
log10 IU/mL) of samples 2e4 against sample 1, for each quantitative
and qualitative assay are shown in Fig. 2. The overall mean esti-
mates (candidate log10 IU/mL) for samples 2e4 relative to sample 1
for the qualitative and quantitative assays, along with the SD (of
log10 estimates) and the %GCV (of actual estimates), are shown in
Table 4. Fig. 2 and Table 4 show that when the mean estimates of
sample 2 are expressed relative to sample 1, there is a marked
improvement in the agreement between laboratories, compared
with Fig. 1. When the mean estimates for samples 3 and 4 are
expressed relative to sample 1 (Fig. 2), there is some improvement
in the agreement between laboratories but it is less marked. For
sample 2, the SD reduced from 0.57 log10 to 0.09 log10, while the %
GCV reduced from 270% to 23%. For samples 3 and 4 the SD reduced
from ~0.6 log10 to 0.46 log10, and the %GCV reduced from ~300% to
187%.
Table 4 also shows the overall mean estimates from all quanti-
tative assays excluding those from laboratories 10,12,16 and 17. The
exclusion of data from these four laboratories further improves the
inter-laboratory agreement for samples 3 and 4 relative to sample 1,
but not for sample 2 relative to sample 1. This is a result of the
apparent differential sensitivity of the assays from laboratories 12
and 17 for the cell-based samples 3 and 4, compared to their results
for cell-free virus samples 1 and 2.
The estimated concentrations of samples 1, 2 and 4 were also
expressed relative to sample 3, using a hypothetical unitage of
106 IU/mL (6.0 log10 IU/mL) for sample 3 (in this case, the hypo-
thetical unitage is based on the overall mean laboratory estimate
for sample 3). The laboratory mean estimates (candidate log10 IU/
mL) are shown in Fig. 3. The overall mean estimates (candidate
log10 IU/mL) for samples 1, 2 and 4 relative to sample 3, along with
the standard deviation (of log10 estimates) and the %GCV (of actual
estimates), from qualitative and quantitative assays, are shown in
Table 5. Fig. 3 and Table 5, show that there is some reduction in
inter-laboratory variability when results for cell-free virus samples
1 and 2 are expressed relative to cell-based sample 3 (the SD for
quantitative assays for samples 1 and 2 reduced from 0.58 and 0.57
to 0.46 and 0.47 respectively, and the %GCV reduced from 277% and
270% to 187% and 197% respectively). The reduction in inter-
Table 4
Overall mean estimates and inter-laboratory variation for potency (log10 IU/mL) relative to sample 1, taking sample 1 as 5  106 (6.7 log10) IU/mL. nd, Not determined.
Sample Assay No. of datasets Mean Range SD %GCV
2 Qualitative 2 6.63 6.31e6.96 nd nd
Quantitative 36 6.74 6.56e6.91 0.09 23
Excluding 10, 12, 16 & 17 32 6.75 6.56e6.91 0.09 23
3 Qualitative 2 5.30 5.04e5.57 nd nd
Quantitative 36 5.90 4.15e7.05 0.46 187
Excluding 10, 12, 16 & 17 32 5.89 5.13e6.57 0.26 84
4 Qualitative 2 6.86 6.56e7.17 nd nd
Quantitative 36 7.43 6.03e8.48 0.46 187
Excluding 10, 12, 16 & 17 32 7.46 6.68e8.12 0.36 130
J.F. Fryer et al. / Biologicals 44 (2016) 423e433 429laboratory variability is greater for sample 4 relative to sample 3
(the SD reduced from 0.63 to 0.32, and the %GCV reduced from
327% to 107%). Table 4 also shows the overall mean estimates from
all quantitative assays excluding those from laboratories 10, 12, 16
and 17. The exclusion of data from these four laboratories further
improves the inter-laboratory agreement for samples 1, 2 and 4
relative to sample 3. Again, this is a result of the differential
sensitivity of the assays from laboratories 12 and 17 for the cell-
based samples 3 and 4, compared with their results for cell-free
virus samples 1 and 2.3.5. Intra-laboratory variation and ‘components of variance’
analysis
Supplementary Table 3 shows the intra-laboratory (between
assay) SDs and %GCVs for the quantitative assays for each labora-
tory. Differences in intra-laboratory variability were observed
across each sample and each laboratory. Intra-assay variability was
higher for cell-based samples 3 and 4 compared with cell-free virus
samples 1 and 2.
The average SD for samples 1 and 2 was 0.14 and 0.15 log10 IU/
mL respectively (average %GCV of approximately 40%). For samples
3 and 4 the average SD was higher at 0.26 log10 IU/mL (average %
GCV of 81%). Some individual laboratories demonstrated poor
repeatability, for example; laboratory 10 for all samples, and labo-
ratories 7A, 12, 16 and 17 for samples 3 and 4 (laboratory 7A used a
separate cell-speciﬁc extraction method for samples 3 and 4).
Table 6 shows the results of a ‘Components of Variance’ analysis
for the quantitative assays. Brieﬂy, this analysis separates the
observed variability in results to an ‘inter-laboratory’ component,
and an ‘intra-laboratory’ (between-assay) component, allowing for
the fact that the observed laboratory means are based on a mean of
four assays in most cases. In all cases, the inter-laboratory variation
was statistically signiﬁcant (p < 0.0001), i.e. the observed differ-
ences between laboratories were not accounted for by intra-
laboratory variability alone. This was true for the results
expressed relative to either sample 1 or sample 3 as well as for the
absolute estimates of ‘copies/mL’. Table 6 shows the variance
components as both SDs (of log10 estimates) and %GCVs. The
equivalent results excluding laboratories 10, 12, 16 & 17 are shown
in Table 7. The %GCVs in Table 6 show that the intra-laboratory
variation of absolute estimates for samples 3 and 4 are double
those for samples 1 and 2. The values are equivalent to the pooled
estimates in Supplementary Table 3. The inter-laboratory compo-
nent is much greater than the intra-laboratory component (%GCV of
approximately 300% vs. 40% for samples 1 and 2, and 80% for
samples 3 and 4). The inter-laboratory component is reduced to
approximately 200% if laboratories 10, 12, 16 and 17 are excluded
(Table 7), while the intra-laboratory components are reduced to
30% for samples 1 and 2, and 70% for samples 3 and 4. This is
because laboratory 10, in particular, has a very high intra-laboratoryvariability (Supplementary Table 3). When the results are
expressed relative to sample 1, the intra-laboratory components are
similar for samples 3 and 4, and lower for sample 2. The inter-
laboratory components are signiﬁcantly reduced for sample 2,
and less so for samples 3 and 4. When the results are expressed
relative to sample 3, the intra-laboratory components are approx-
imately 90% for all samples. The inter-laboratory components are
approximately 200% for samples 1 and 2, and approximately 100%
for sample 4.4. Discussion
Viral load measurements are increasingly important in the
clinical management of infectious diseases. It is critical that these
measurements are accurate and comparable across the range of
assays in use, in order that data between different clinical studies
separated by location and time can be compared and optimal
treatment strategies established. Over the past 20 years, NIBSC, in
collaboration with the WHO ECBS, has helped to support the
introduction of NAT assays into the blood safety ﬁeld, through the
development of International Standards and other reference ma-
terials for blood-borne viruses. We have recently applied these
principles to support the standardisation of HCMV viral load
measurements [17]. Here we describe the development of a WHO
International Standard for EBV for NAT. The aimwas tomake a large
batch of aliquots of a stable and homogenous preparation suitable
for a range of NAT-based assays.
In this study, four candidates were evaluated for their suitability
and potency as the 1stWHO International Standard for EBV for NAT.
These included liquid and lyophilised live virus preparations of
B95-8, and preparations of Namalwa and Raji cells. These EBV
strains were selected for the study as they are well characterised
and widely used in the development of EBV NAT-based assays and
controls. The B95-8 virus has previously been sequenced and the
data deposited in GenBank (Accession no. NC_007605) [18]. The
formulation of whole virus and cell-based preparations enables the
candidates to be extracted alongside assay controls and clinical
samples, thereby standardising the entire EBV assay, including both
extraction and DNA ampliﬁcation steps. Compared with the blood-
borne viruses, where virus is principally detected in one sample
matrix (i.e. plasma), the design of a reference material for a clinical
virus such as EBV is particularly challenging, because of the number
of clinical substrates in which the virus is detected. Given the wide
range of samples that are routinely tested for EBV, and the different
extraction methods designed to process each sample type, the
whole virus candidates were formulated in a universal TriseHSA
buffer, to allow for further dilution in the appropriate sample ma-
trix used in each laboratory assay. Similarly, the Namalwa and Raji
preparations were formulated in PBS. The intention here was to
provide a single reference material for EBV that could be processed
using all extraction protocols available for EBV-positive samples. A
Fig. 3. Estimated concentrations (expressed in IU) of sample 1 relative to sample 3 (A),
sample 2 relative to sample 3 (B), and sample 4 relative to sample 3 (C), using a hy-
pothetical unitage of 106 IU/mL for sample 3. Each box represents the relative potency
for each laboratory assay and is labelled with the laboratory code number. The results
from the qualitative assays are labelled Q. The results are colour coded according to the
diluent used in the assay (dark grey, whole blood; light grey, plasma; white, other).
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shipping at ambient temperatures, and for long-term stability for
the lifetime of the product, which is anticipated to be 10e15 years.
Data from accelerated thermal degradation studies up to 72months
suggests that there would be no drop in potency upon storage
at 20 C for this length of time. As there is no observed drop in
potency, it is not possible to ﬁt the usual Arrhenius model for
accelerated degradation studies, or to obtain any predictions for the
expected loss per year with long-term storage at 20 C. However,
using the ‘rule of thumb’ that the decay rate will approximately
double with every 10 C increase in temperature (personal
communication: Dr. P K Philips), and noting that there is no
detectable drop in potency after 72 months at þ20 C, then there
should be no detectable difference after 90 years at20 C. Overall,
all available data indicates adequate stability.
In the collaborative study, all assays detected B95-8, Raji and
Namalwa strains, demonstrating the suitability of these strains for
use as candidate reference materials. The overall mean estimates
for the B95-8 candidates were 5 106 (6.7 log10) ‘copies/mL’. This is
slightly lower than the original target concentration of 1  107
‘copies/mL’, and is likely to be due to the small subset of labora-
tories selected for preliminary testing of the B95-8 stock, and the
large inter-laboratory variation observed in assay results. Individual
laboratory mean estimates ranged from 5.03 to 7.56 log10 ‘copies/
mL’. It was noted that a PCR target based on the BamHI-W repeat
fragment was used by two participants (laboratories 10 and 15).
This fragment is repeated approximately 6e20 times indifferent
EBV isolates, which can lead to over-quantiﬁcation of EBV DNA in
certain sample types (e.g. plasma), especially when these contain
fragmented DNA. Therefore, the use of this sequence in EBV viral
load measurement is generally not advised (personal communi-
cation: Prof. J Middeldorp). However, in this evaluation laboratories
10 and 15 did not report higher EBV concentrations for these study
samples compared to other participants.
The overall range in laboratory mean estimates for all study
samples was 2.5 log10. This variability reﬂects the range and dif-
ferences in diagnostic testing procedures between laboratories and
is similar to levels previously reported for EBV NAT assays [5]. The
agreement between laboratories for virus sample 2 was markedly
improved when the potency was expressed relative to the lyophi-
lised B95-8 candidate (sample 1), demonstrating the suitability of
whole virus virus-based candidates to reduce inter-laboratory
variability of assays testing similar virus samples. The agreement
between laboratories for cell samples 3 and 4 was also improved
when the potencies were expressed relative to the lyophilised B95-
8 candidate (sample 1), however, the improvement was less
marked than for sample 2. This may be due to greater variability in
the extraction efﬁciencies for cell-based samples or possible het-
erogeneity of the cell-based samples 3 and 4. Inter-laboratory
variability was signiﬁcantly higher than intra-laboratory vari-
ability, as reported in other studies [5,6]. Intra-laboratory vari-
ability was higher for cell-based samples 3 and 4 compared with
virus samples 1 and 2. This ﬁnding was also reported by Preiksaitis
et al. [5], illustrating the possible differences in and the need to
validate extraction efﬁciencies between cell-free and cell-based
samples.
From the results of this collaborative study, the lyophilised B95-
8 whole virus preparation was determined to be the optimal
candidate for a higher order reference for EBV quantiﬁcation. It
represents a well characterised EBV strain, and can be used to
standardise the entire NAT assay including the extraction step. It is
also stable and suitable for long-term use. The study data was
reviewed by theWHO ECBS in October 2011, and this candidate was
established as the 1st WHO International Standard for EBV for NAT-
based assays, with an assigned potency of 5  106 International
Table 5
Overall mean estimates and inter-laboratory variation for potency (log10 IU/mL) relative to sample 3, taking sample 1 as 106 (6.0 log10) IU/mL. nd, not determined.
Sample Assay No. of datasets Mean Range SD %GCV
1 Qualitative 2 7.40 7.13e7.66 nd nd
Quantitative 36 6.80 5.65e8.55 0.46 187
Excluding 10, 12, 16 & 17 32 6.81 6.13e7.57 0.26 84
2 Qualitative 2 7.33 6.74e7.92 nd nd
Quantitative 36 6.84 5.61e8.60 0.47 197
Excluding 10, 12, 16 & 17 32 6.86 6.32e7.73 0.27 86
4 Qualitative 2 7.56 6.99e8.13 nd nd
Quantitative 36 7.53 6.32e8.13 0.32 107
Excluding 10, 12, 16 & 17 32 7.57 6.95e8.13 0.25 76
Table 6
Components of variance, inter vs. intra-laboratory contributions for all quantitative assays (36 datasets).
Component Sample SD %GCV
Inter-laboratory Intra-laboratory Inter-laboratory Intra-laboratory
Absolute estimates (copies/mL) 1 0.57 0.14 273 38
2 0.56 0.15 267 41
3 0.60 0.26 293 81
4 0.62 0.26 320 82
Potencies relative to sample 1 1 e e e e
2 0.07 0.10 19 24
3 0.46 0.28 185 90
4 0.44 0.25 177 79
Potencies relative to sample 3 1 0.46 0.28 185 90
2 0.47 0.27 196 87
3 e e e e
4 0.30 0.28 98 88
Table 7
Components of variance, inter vs. intra-laboratory contributions for quantitative assays, excluding laboratories 10, 12, 16 & 17 (32 datasets).
Component Sample SD %GCV
Inter-laboratory Intra-laboratory Inter-laboratory Intra-laboratory
Absolute estimates (copies/mL) 1 0.48 0.11 203 30
2 0.46 0.12 185 33
3 0.48 0.23 200 71
4 0.48 0.24 202 73
Potencies relative to sample 1 1 e e e e
2 0.08 0.09 19 24
3 0.24 0.24 75 75
4 0.34 0.24 120 72
Potencies relative to sample 3 1 0.24 0.24 75 75
2 0.25 0.24 78 75
3 e e e e
4 0.21 0.27 63 84
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code 09/260) [19]. The assignment of a unitage for a 1st WHO In-
ternational Standard is arbitrary. However, in the case of this study,
a value of 5  106 IU was chosen as this represents the consensus
estimate for the candidate standard across all laboratory assays. The
assigned unitage does not carry an uncertainty associated with its
calibration. The uncertainty may therefore be considered to be the
variance of the vial content and was determined to be ±0.23%. As
this study shows, the use of the term copy number for virus
quantiﬁcation by NAT can be misleading. Copy number estimates
are not necessarily equivalent to genuine genome equivalent
numbers, but are instead dependent upon variables in the extrac-
tion and ampliﬁcation steps, and on the quantiﬁcation controls
used. As for the International Standards established for the blood-
borne viruses, there is no overall conversion factor between
copies and IUs for EBV. Any conversion may be applied to a speciﬁc
assay when it has been calibrated against the International
Standard.The EBV International Standard is intended to be used for the
calibration of whole virus-based secondary reference materials
used in EBV NAT assays. This can be performed by assaying serial
dilutions of both preparations in parallel and determining the
equivalent concentration of the secondary reference in IU. Once
reconstituted, the EBV International Standard should be diluted in
the matrix appropriate to the material being calibrated, and
extracted and ampliﬁed in parallel with the secondary reference.
The stability of the material when reconstituted has not been
speciﬁcally determined. Therefore, it is recommended that the
standard is for single use only.
The ability of the lyophilised B95-8 candidate to reduce inter-
laboratory variability for the samples investigated in this study
does not necessarily guarantee that, when widely implemented,
the EBV International Standard will harmonise EBV NAT assays in
the same way. The accuracy of measurement of a virus in a clinical
sample relies on the ability of the reference or control samples to
behave like clinical samples, i.e. to demonstrate commutability.
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demonstrated for all references used in the measurement process,
i.e. both the secondary reference included within each individual
assay run and the higher order primary reference against which it is
calibrated. Commutability can be affected by a range of factors
including the matrix and molecular variants of the analyte (i.e.
intracellular vs. extracellular or encapsidated vs. naked nature of
the DNA, and EBV strain variants).
The commutability of each candidate for EBV-positive clinical
samples was not speciﬁcally assessed in this study. It was not
feasible to derive the candidates from EBV-positive clinical mate-
rial, as has been the case for other WHO International Standards
such as those for HAV, HBV and HCV [21e23]. The differing pa-
thology of EBV infections in the various disease states is such that a
range of types of patient samples, particularly different blood
components (described in Section 1), are routinely tested for EBV
DNA. This complexity also makes it difﬁcult to produce a single
reference material to be used as the EBV International Standard.
The choice of strains and formulation for the candidates were
intended to make them as similar as possible to the range of
samples being investigated for EBV. The purpose of formulating the
candidates in a universal matrix for subsequent dilution in the
sample matrix appropriate to each assay was to try to control for
matrix effects. The results suggest that there was no apparent
relationship between the matrix used as the diluent in this study
and the estimate of ‘copies/mL’. However, it is evident that cell-free
virus diluted in whole blood does not represent an EBV-positive
whole blood from an immunosuppressed individual, where virus
is cell-associated at least in part. Indeed, the results suggest that
there was a difference in the ability of the cell-free candidates to
reduce the variability of viral load measurements of cell-free vs.
cell-associated EBV preparations. This may again be due to the
different efﬁciencies in extracting different sample types, possible
heterogeneity of the cell-based samples 3 and 4, or to other matrix
effects.
In addition, the nature of the EBV DNA present within each
sample type differs depending on the disease state and stage of
infection. EBV DNA in the plasma of NPC patients is principally
naked and fragmented [24]. Meanwhile in PTLD, it is cell-associated
although smaller amounts of naked DNA and encapsidated virus (in
primary infection) may also be present in plasma. In this study, the
B95-8 candidates were derived from a crude cell-free preparation
of EBV from cell culture, which comprises both whole virus and
naked EBV DNA (as determined by DNase digestion experiments e
data not shown). All assays used in the collaborative study evalu-
ationwere able to detect the three EBV Type I strains represented in
the study, suggesting that the EBV B95-8 International Standard
would be suitable for the calibration of secondary references
comprising these virus strains. It was not feasible to examine
further EBV strains (such as Type II strains) within the context of
this collaborative study because of the work load required by the
participants. However, the majority of EBV NAT assays do not
distinguish between EBV types.
A full assessment of commutability would require the reference
material to be evaluated in all assays and alongside all sample types
for which it might be used. This is because commutability can only
be demonstrated for the assays and clinical samples for which the
reference has been assessed. This task is particularly challenging for
EBV because of the number of assays in use (as highlighted in this
collaborative study), and also because of the range of sample types
that are tested. The difﬁculty in sourcing sufﬁcient volumes of
clinical material for such extensive studies would require pooling
or dilution of samples thereby potentially compromising matrix
effects. This difﬁculty means that commutability will most likely
need to be addressed in multiple studies.Commutability of the EBV International Standard with EBV-
positive plasma samples was recently determined for two EBV
NAT assays [25]. In this report, 40 EBV-positive plasma samples
were tested alongside dilutions of the EBV International Standard
using a commercial assay and an in-house assay based on the
BamHI target. The results indicated that in these two assays the EBV
International Standard behaved similarly to the clinical samples
and was therefore determined to be commutable. Further com-
mutability studies are planned to investigate the commutability of
the EBV International Standard with respect to EBV DNA forms
present in other clinical samples. Any evidence for non-
commutability might restrict its use with speciﬁc assays or sam-
ple types. In the meantime, the availability of the EBV International
Standard provides a higher order reference that will facilitate the
characterisation and standardisation of the factors that contribute
to assay variability, and assist in the development of uniform
management strategies for EBV-associated diseases with consensus
EBV viral load thresholds for intervention deﬁned in IU.
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